Eli Lilly Holds Near All-Time Highs as Stock Dips Slightly to $1,429

By TrendSpider Editor

Eli Lilly and Company shares slipped just 0.10% on Friday, November 13, 2026, settling at $1,429.36 after trading in a previous session range of $1,414.77 to $1,440.35. Despite the marginal pullback, LLY remains within striking distance of its 52-week high of $1,453, underscoring the stock's sustain

Eli Lilly Holds Near All-Time Highs as Stock Dips Slightly to $1,429

Eli Lilly and Company shares slipped just 0.10% on Friday, November 13, 2026, settling at $1,429.36 after trading in a previous session range of $1,414.77 to $1,440.35. Despite the marginal pullback, LLY remains within striking distance of its 52-week high of $1,453, underscoring the stock's sustained momentum after rebounding sharply from its 52-week low of $850.51. The proximity to record levels reflects durable investor confidence in Lilly's pipeline and commercial execution over the past year.

Key Drivers of the LLY Stock Move

The forward setup for LLY remains constructive from a technical standpoint. The stock has built a base near all-time highs, which is historically a sign of accumulation rather than exhaustion when volume and momentum are supportive. The narrow daily range on Friday, with a session low of $1,414.77 and high of $1,440.35, indicates controlled selling rather than any aggressive unwinding. Investors will be watching whether Lilly can muster a decisive push above $1,453 to establish a fresh 52-week high, or whether resistance at that level will hold and trigger a broader consolidation phase heading into year-end.

LLY Seasonality

Mid-November historically marks the beginning of a seasonally favorable stretch for large-cap pharmaceutical names, as portfolio managers look to add defensive, high-growth healthcare exposure ahead of year-end rebalancing. For a stock already pressing against 52-week highs in this window, seasonal tailwinds could provide an incremental catalyst for a breakout attempt.

LLY Relative Performance

At $1,429.36 and within 1.63% of its 52-week high of $1,453, LLY is significantly outperforming the broader pharmaceutical sector on a trailing basis, having more than recovered from the $850.51 low set earlier in the 52-week period. The stock's ability to hold above $1,400 while the broader market navigates mixed signals on a Friday session speaks to its relative defensive and growth appeal among mega-cap healthcare peers.

More on LLY

Latest Market News